Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial
Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is characterized by vascular obstruction and remodeling, leading to i...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2008-12, Vol.52 (25), p.2127-2134 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2134 |
|---|---|
| container_issue | 25 |
| container_start_page | 2127 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 52 |
| creator | JAÏS, Xavier D'ARMINI, Andrea M PERCHENET, Loïc MORGANTI, Adele SIMONNEAU, Gérald RUBIN, Lewis J JANSA, Pavel TORBICKI, Adam DELCROIX, Marion GHOFRANI, Hossein A HOEPER, Marius M LANG, Irene M MAYER, Eckhard PEPKE-ZABA, Joanna |
| description | Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is characterized by vascular obstruction and remodeling, leading to increased pulmonary vascular resistance (PVR). Although pulmonary endarterectomy (PEA) is potentially curative, medical therapy is needed in patients with inoperable disease or persistent/recurrent pulmonary hypertension after PEA.
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension) study was a double-blind, randomized, placebo-controlled study in CTEPH including patients with either inoperable CTEPH or persistent/recurrent pulmonary hypertension after PEA (>6 months after PEA). Independent coprimary end points were change in PVR as a percentage of baseline and change from baseline in 6-min walk distance after 16 weeks of treatment with bosentan or placebo. Secondary end points included change from baseline in World Health Organization functional class and other hemodynamic parameters.
One hundred fifty-seven patients were enrolled and randomized: 80 to placebo, 77 to bosentan. A statistically significant treatment effect (TE) of bosentan over placebo on PVR was demonstrated: -24.1% of baseline (95% confidence interval [CI]: -31.5% to -16.0%; p < 0.0001). Total pulmonary resistance (TE: -193 dynxsxcm(-5); 95% CI: -283 to -104 dyn.s.cm(-5); p < 0.0001) and cardiac index (TE: 0.3 lxmin(-1)xm(-2); 95% CI: 0.14 to 0.46 lxmin(-1)xm(-2); p = 0.0007) improved. Mean TE on 6-min walk distance was +2.2 m (95% CI: -22.5 to 26.8 m; p = 0.5449). Bosentan treatment was well tolerated.
This study demonstrated a positive TE of bosentan on hemodynamics in this patient population. No improvement was observed in exercise capacity. Further trials are needed to define the role of medical therapy in patients with CTEPH (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension; NCT00313222). |
| doi_str_mv | 10.1016/j.jacc.2008.08.059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69910343</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3243003611</sourcerecordid><originalsourceid>FETCH-LOGICAL-h218t-eba0d374943116045f6a85e25c649d19f5413a7f3aacc073bb2519fd55b0fbd23</originalsourceid><addsrcrecordid>eNptkdFqHCEUhqU0NNu0L9CLIpSWBjJbHXVm7F2yzDaBkIayvR7UUdbF0YnOXCTP2oepS7ZLKQUPh3P4-H_9BeAdRkuMcPVlt9wJpZYlQs1yfxh_ARaYsaYgjNcvwQLVhBUY8foUvE5phxCqGsxfgVPMEWe45Avw6yok7SfhoQkRbqIW05BnGAy88WHUUUin4Wobg7cKbnIfZNC5XB7vZzcEL-IjvH7M6KR9ssHDr_CqvWvXdgM_H9VbY7SaErQe2rswts-66xCHtPdS_zcYjwbbvwzOL6CAP4Tvw2CfdH8B751QWoZiFfwUg3O6zy-xwr0BJ0a4pN8e-hn4uW43q-vi9vu3m9XlbbEtcTMVWgrUk5pySjCuEGWmEg3TJVMV5T3mhlFMRG2IyHHnTKUsWd72jElkZF-SM_DpWXeM4WHWaeoGm5R2Tngd5tRVnGNEKMngh3_AXZijz3frMENVSSmje7n3B2qWg-67MdohZ9D9-bUMfDwAIinhTBRe2XTkSsQrxmpEfgPi16th</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506244542</pqid></control><display><type>article</type><title>Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>JAÏS, Xavier ; D'ARMINI, Andrea M ; PERCHENET, Loïc ; MORGANTI, Adele ; SIMONNEAU, Gérald ; RUBIN, Lewis J ; JANSA, Pavel ; TORBICKI, Adam ; DELCROIX, Marion ; GHOFRANI, Hossein A ; HOEPER, Marius M ; LANG, Irene M ; MAYER, Eckhard ; PEPKE-ZABA, Joanna</creator><creatorcontrib>JAÏS, Xavier ; D'ARMINI, Andrea M ; PERCHENET, Loïc ; MORGANTI, Adele ; SIMONNEAU, Gérald ; RUBIN, Lewis J ; JANSA, Pavel ; TORBICKI, Adam ; DELCROIX, Marion ; GHOFRANI, Hossein A ; HOEPER, Marius M ; LANG, Irene M ; MAYER, Eckhard ; PEPKE-ZABA, Joanna ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group</creatorcontrib><description>Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is characterized by vascular obstruction and remodeling, leading to increased pulmonary vascular resistance (PVR). Although pulmonary endarterectomy (PEA) is potentially curative, medical therapy is needed in patients with inoperable disease or persistent/recurrent pulmonary hypertension after PEA.
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension) study was a double-blind, randomized, placebo-controlled study in CTEPH including patients with either inoperable CTEPH or persistent/recurrent pulmonary hypertension after PEA (>6 months after PEA). Independent coprimary end points were change in PVR as a percentage of baseline and change from baseline in 6-min walk distance after 16 weeks of treatment with bosentan or placebo. Secondary end points included change from baseline in World Health Organization functional class and other hemodynamic parameters.
One hundred fifty-seven patients were enrolled and randomized: 80 to placebo, 77 to bosentan. A statistically significant treatment effect (TE) of bosentan over placebo on PVR was demonstrated: -24.1% of baseline (95% confidence interval [CI]: -31.5% to -16.0%; p < 0.0001). Total pulmonary resistance (TE: -193 dynxsxcm(-5); 95% CI: -283 to -104 dyn.s.cm(-5); p < 0.0001) and cardiac index (TE: 0.3 lxmin(-1)xm(-2); 95% CI: 0.14 to 0.46 lxmin(-1)xm(-2); p = 0.0007) improved. Mean TE on 6-min walk distance was +2.2 m (95% CI: -22.5 to 26.8 m; p = 0.5449). Bosentan treatment was well tolerated.
This study demonstrated a positive TE of bosentan on hemodynamics in this patient population. No improvement was observed in exercise capacity. Further trials are needed to define the role of medical therapy in patients with CTEPH (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension; NCT00313222).</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2008.08.059</identifier><identifier>PMID: 19095129</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology ; Cardiology. Vascular system ; Chronic Disease ; Confidence intervals ; Disease Progression ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Double-Blind Method ; Drug therapy ; Embolisms ; Endarterectomy ; Endothelin Receptor Antagonists ; Exercise Tolerance - drug effects ; Female ; Hemodynamics - drug effects ; Humans ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - etiology ; Hypertension, Pulmonary - surgery ; Lung diseases ; Male ; Medical imaging ; Medical prognosis ; Medical sciences ; Middle Aged ; Mortality ; Pneumology ; Prognosis ; Pulmonary arteries ; Pulmonary hypertension ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Severity of Illness Index ; Sulfonamides - therapeutic use ; Surgery ; Thromboembolism - complications</subject><ispartof>Journal of the American College of Cardiology, 2008-12, Vol.52 (25), p.2127-2134</ispartof><rights>2009 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 16, 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27902,27903</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20965570$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19095129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JAÏS, Xavier</creatorcontrib><creatorcontrib>D'ARMINI, Andrea M</creatorcontrib><creatorcontrib>PERCHENET, Loïc</creatorcontrib><creatorcontrib>MORGANTI, Adele</creatorcontrib><creatorcontrib>SIMONNEAU, Gérald</creatorcontrib><creatorcontrib>RUBIN, Lewis J</creatorcontrib><creatorcontrib>JANSA, Pavel</creatorcontrib><creatorcontrib>TORBICKI, Adam</creatorcontrib><creatorcontrib>DELCROIX, Marion</creatorcontrib><creatorcontrib>GHOFRANI, Hossein A</creatorcontrib><creatorcontrib>HOEPER, Marius M</creatorcontrib><creatorcontrib>LANG, Irene M</creatorcontrib><creatorcontrib>MAYER, Eckhard</creatorcontrib><creatorcontrib>PEPKE-ZABA, Joanna</creatorcontrib><creatorcontrib>Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group</creatorcontrib><title>Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is characterized by vascular obstruction and remodeling, leading to increased pulmonary vascular resistance (PVR). Although pulmonary endarterectomy (PEA) is potentially curative, medical therapy is needed in patients with inoperable disease or persistent/recurrent pulmonary hypertension after PEA.
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension) study was a double-blind, randomized, placebo-controlled study in CTEPH including patients with either inoperable CTEPH or persistent/recurrent pulmonary hypertension after PEA (>6 months after PEA). Independent coprimary end points were change in PVR as a percentage of baseline and change from baseline in 6-min walk distance after 16 weeks of treatment with bosentan or placebo. Secondary end points included change from baseline in World Health Organization functional class and other hemodynamic parameters.
One hundred fifty-seven patients were enrolled and randomized: 80 to placebo, 77 to bosentan. A statistically significant treatment effect (TE) of bosentan over placebo on PVR was demonstrated: -24.1% of baseline (95% confidence interval [CI]: -31.5% to -16.0%; p < 0.0001). Total pulmonary resistance (TE: -193 dynxsxcm(-5); 95% CI: -283 to -104 dyn.s.cm(-5); p < 0.0001) and cardiac index (TE: 0.3 lxmin(-1)xm(-2); 95% CI: 0.14 to 0.46 lxmin(-1)xm(-2); p = 0.0007) improved. Mean TE on 6-min walk distance was +2.2 m (95% CI: -22.5 to 26.8 m; p = 0.5449). Bosentan treatment was well tolerated.
This study demonstrated a positive TE of bosentan on hemodynamics in this patient population. No improvement was observed in exercise capacity. Further trials are needed to define the role of medical therapy in patients with CTEPH (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension; NCT00313222).</description><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Chronic Disease</subject><subject>Confidence intervals</subject><subject>Disease Progression</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Embolisms</subject><subject>Endarterectomy</subject><subject>Endothelin Receptor Antagonists</subject><subject>Exercise Tolerance - drug effects</subject><subject>Female</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Hypertension, Pulmonary - surgery</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Pulmonary arteries</subject><subject>Pulmonary hypertension</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>Severity of Illness Index</subject><subject>Sulfonamides - therapeutic use</subject><subject>Surgery</subject><subject>Thromboembolism - complications</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkdFqHCEUhqU0NNu0L9CLIpSWBjJbHXVm7F2yzDaBkIayvR7UUdbF0YnOXCTP2oepS7ZLKQUPh3P4-H_9BeAdRkuMcPVlt9wJpZYlQs1yfxh_ARaYsaYgjNcvwQLVhBUY8foUvE5phxCqGsxfgVPMEWe45Avw6yok7SfhoQkRbqIW05BnGAy88WHUUUin4Wobg7cKbnIfZNC5XB7vZzcEL-IjvH7M6KR9ssHDr_CqvWvXdgM_H9VbY7SaErQe2rswts-66xCHtPdS_zcYjwbbvwzOL6CAP4Tvw2CfdH8B751QWoZiFfwUg3O6zy-xwr0BJ0a4pN8e-hn4uW43q-vi9vu3m9XlbbEtcTMVWgrUk5pySjCuEGWmEg3TJVMV5T3mhlFMRG2IyHHnTKUsWd72jElkZF-SM_DpWXeM4WHWaeoGm5R2Tngd5tRVnGNEKMngh3_AXZijz3frMENVSSmje7n3B2qWg-67MdohZ9D9-bUMfDwAIinhTBRe2XTkSsQrxmpEfgPi16th</recordid><startdate>20081216</startdate><enddate>20081216</enddate><creator>JAÏS, Xavier</creator><creator>D'ARMINI, Andrea M</creator><creator>PERCHENET, Loïc</creator><creator>MORGANTI, Adele</creator><creator>SIMONNEAU, Gérald</creator><creator>RUBIN, Lewis J</creator><creator>JANSA, Pavel</creator><creator>TORBICKI, Adam</creator><creator>DELCROIX, Marion</creator><creator>GHOFRANI, Hossein A</creator><creator>HOEPER, Marius M</creator><creator>LANG, Irene M</creator><creator>MAYER, Eckhard</creator><creator>PEPKE-ZABA, Joanna</creator><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20081216</creationdate><title>Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial</title><author>JAÏS, Xavier ; D'ARMINI, Andrea M ; PERCHENET, Loïc ; MORGANTI, Adele ; SIMONNEAU, Gérald ; RUBIN, Lewis J ; JANSA, Pavel ; TORBICKI, Adam ; DELCROIX, Marion ; GHOFRANI, Hossein A ; HOEPER, Marius M ; LANG, Irene M ; MAYER, Eckhard ; PEPKE-ZABA, Joanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h218t-eba0d374943116045f6a85e25c649d19f5413a7f3aacc073bb2519fd55b0fbd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Chronic Disease</topic><topic>Confidence intervals</topic><topic>Disease Progression</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Embolisms</topic><topic>Endarterectomy</topic><topic>Endothelin Receptor Antagonists</topic><topic>Exercise Tolerance - drug effects</topic><topic>Female</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Hypertension, Pulmonary - surgery</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Pulmonary arteries</topic><topic>Pulmonary hypertension</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>Severity of Illness Index</topic><topic>Sulfonamides - therapeutic use</topic><topic>Surgery</topic><topic>Thromboembolism - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JAÏS, Xavier</creatorcontrib><creatorcontrib>D'ARMINI, Andrea M</creatorcontrib><creatorcontrib>PERCHENET, Loïc</creatorcontrib><creatorcontrib>MORGANTI, Adele</creatorcontrib><creatorcontrib>SIMONNEAU, Gérald</creatorcontrib><creatorcontrib>RUBIN, Lewis J</creatorcontrib><creatorcontrib>JANSA, Pavel</creatorcontrib><creatorcontrib>TORBICKI, Adam</creatorcontrib><creatorcontrib>DELCROIX, Marion</creatorcontrib><creatorcontrib>GHOFRANI, Hossein A</creatorcontrib><creatorcontrib>HOEPER, Marius M</creatorcontrib><creatorcontrib>LANG, Irene M</creatorcontrib><creatorcontrib>MAYER, Eckhard</creatorcontrib><creatorcontrib>PEPKE-ZABA, Joanna</creatorcontrib><creatorcontrib>Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JAÏS, Xavier</au><au>D'ARMINI, Andrea M</au><au>PERCHENET, Loïc</au><au>MORGANTI, Adele</au><au>SIMONNEAU, Gérald</au><au>RUBIN, Lewis J</au><au>JANSA, Pavel</au><au>TORBICKI, Adam</au><au>DELCROIX, Marion</au><au>GHOFRANI, Hossein A</au><au>HOEPER, Marius M</au><au>LANG, Irene M</au><au>MAYER, Eckhard</au><au>PEPKE-ZABA, Joanna</au><aucorp>Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2008-12-16</date><risdate>2008</risdate><volume>52</volume><issue>25</issue><spage>2127</spage><epage>2134</epage><pages>2127-2134</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is characterized by vascular obstruction and remodeling, leading to increased pulmonary vascular resistance (PVR). Although pulmonary endarterectomy (PEA) is potentially curative, medical therapy is needed in patients with inoperable disease or persistent/recurrent pulmonary hypertension after PEA.
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension) study was a double-blind, randomized, placebo-controlled study in CTEPH including patients with either inoperable CTEPH or persistent/recurrent pulmonary hypertension after PEA (>6 months after PEA). Independent coprimary end points were change in PVR as a percentage of baseline and change from baseline in 6-min walk distance after 16 weeks of treatment with bosentan or placebo. Secondary end points included change from baseline in World Health Organization functional class and other hemodynamic parameters.
One hundred fifty-seven patients were enrolled and randomized: 80 to placebo, 77 to bosentan. A statistically significant treatment effect (TE) of bosentan over placebo on PVR was demonstrated: -24.1% of baseline (95% confidence interval [CI]: -31.5% to -16.0%; p < 0.0001). Total pulmonary resistance (TE: -193 dynxsxcm(-5); 95% CI: -283 to -104 dyn.s.cm(-5); p < 0.0001) and cardiac index (TE: 0.3 lxmin(-1)xm(-2); 95% CI: 0.14 to 0.46 lxmin(-1)xm(-2); p = 0.0007) improved. Mean TE on 6-min walk distance was +2.2 m (95% CI: -22.5 to 26.8 m; p = 0.5449). Bosentan treatment was well tolerated.
This study demonstrated a positive TE of bosentan on hemodynamics in this patient population. No improvement was observed in exercise capacity. Further trials are needed to define the role of medical therapy in patients with CTEPH (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension; NCT00313222).</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>19095129</pmid><doi>10.1016/j.jacc.2008.08.059</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2008-12, Vol.52 (25), p.2127-2134 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69910343 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antihypertensive Agents - therapeutic use Biological and medical sciences Blood and lymphatic vessels Cardiology Cardiology. Vascular system Chronic Disease Confidence intervals Disease Progression Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Double-Blind Method Drug therapy Embolisms Endarterectomy Endothelin Receptor Antagonists Exercise Tolerance - drug effects Female Hemodynamics - drug effects Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - etiology Hypertension, Pulmonary - surgery Lung diseases Male Medical imaging Medical prognosis Medical sciences Middle Aged Mortality Pneumology Prognosis Pulmonary arteries Pulmonary hypertension Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Severity of Illness Index Sulfonamides - therapeutic use Surgery Thromboembolism - complications |
| title | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension : BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T08%3A43%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bosentan%20for%20Treatment%20of%20Inoperable%20Chronic%20Thromboembolic%20Pulmonary%20Hypertension%20:%20BENEFiT%20(Bosentan%20Effects%20in%20iNopErable%20Forms%20of%20chronic%20Thromboembolic%20pulmonary%20hypertension),%20a%20Randomized,%20Placebo-Controlled%20Trial&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=JA%C3%8FS,%20Xavier&rft.aucorp=Bosentan%20Effects%20in%20iNopErable%20Forms%20of%20chronIc%20Thromboembolic%20pulmonary%20hypertension%20Study%20Group&rft.date=2008-12-16&rft.volume=52&rft.issue=25&rft.spage=2127&rft.epage=2134&rft.pages=2127-2134&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/j.jacc.2008.08.059&rft_dat=%3Cproquest_pubme%3E3243003611%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1506244542&rft_id=info:pmid/19095129&rfr_iscdi=true |